BioMark Diagnostics Inc. (BUX.CN)
CAD 0.25
(0.0%)
CAD 0.25
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.47 Million CAD | -16.38% |
| 2022 | 1.88 Million CAD | 30.31% |
| 2021 | 1.44 Million CAD | 34.0% |
| 2020 | 1.07 Million CAD | -26.65% |
| 2019 | 1.47 Million CAD | 169.85% |
| 2018 | 545.61 Thousand CAD | -24.92% |
| 2017 | 726.74 Thousand CAD | 0.8% |
| 2016 | 721 Thousand CAD | -48.78% |
| 2015 | 1.4 Million CAD | -51.2% |
| 2014 | 2.88 Million CAD | 1493.6% |
| 2013 | 180.99 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 642.61 Thousand CAD | 34.08% |
| 2023 FY | 1.57 Million CAD | -16.38% |
| 2023 Q2 | 428.37 Thousand CAD | -1.13% |
| 2023 Q1 | 433.29 Thousand CAD | -15.31% |
| 2023 Q3 | 383.04 Thousand CAD | -10.58% |
| 2023 Q4 | 436.2 Thousand CAD | 13.88% |
| 2022 Q1 | 426.78 Thousand CAD | -40.49% |
| 2022 FY | 1.88 Million CAD | 30.31% |
| 2022 Q4 | 511.64 Thousand CAD | 25.31% |
| 2022 Q3 | 408.3 Thousand CAD | -24.22% |
| 2022 Q2 | 538.83 Thousand CAD | 26.25% |
| 2021 Q2 | 177.92 Thousand CAD | -37.71% |
| 2021 FY | 1.44 Million CAD | 34.0% |
| 2021 Q4 | 717.11 Thousand CAD | 169.21% |
| 2021 Q3 | 266.37 Thousand CAD | 49.72% |
| 2021 Q1 | 285.62 Thousand CAD | -49.87% |
| 2020 FY | 1.07 Million CAD | -26.65% |
| 2020 Q4 | 569.81 Thousand CAD | 193.43% |
| 2020 Q2 | 187.45 Thousand CAD | 42.89% |
| 2020 Q3 | 194.18 Thousand CAD | 3.59% |
| 2020 Q1 | 131.18 Thousand CAD | -53.09% |
| 2019 Q3 | 936.17 Thousand CAD | 588.74% |
| 2019 Q4 | 279.67 Thousand CAD | -70.13% |
| 2019 FY | 1.47 Million CAD | 169.85% |
| 2019 Q1 | 120.55 Thousand CAD | -2.16% |
| 2019 Q2 | 135.92 Thousand CAD | 12.75% |
| 2018 FY | 545.61 Thousand CAD | -24.92% |
| 2018 Q4 | 123.21 Thousand CAD | -26.95% |
| 2018 Q3 | 168.66 Thousand CAD | 5.05% |
| 2018 Q1 | 110.91 Thousand CAD | -21.83% |
| 2018 Q2 | 160.55 Thousand CAD | 44.76% |
| 2017 Q3 | 176.37 Thousand CAD | -19.25% |
| 2017 FY | 726.74 Thousand CAD | 0.8% |
| 2017 Q1 | 190.06 Thousand CAD | -21.91% |
| 2017 Q2 | 218.42 Thousand CAD | 14.92% |
| 2017 Q4 | 141.88 Thousand CAD | -19.56% |
| 2016 Q1 | 215.53 Thousand CAD | -69.24% |
| 2016 FY | 721 Thousand CAD | -48.78% |
| 2016 Q4 | 243.4 Thousand CAD | 117.8% |
| 2016 Q3 | 111.75 Thousand CAD | -25.65% |
| 2016 Q2 | 150.3 Thousand CAD | -30.26% |
| 2015 FY | 1.4 Million CAD | -51.2% |
| 2015 Q1 | 209.29 Thousand CAD | -70.36% |
| 2015 Q3 | 260.89 Thousand CAD | 10.27% |
| 2015 Q4 | 700.74 Thousand CAD | 168.6% |
| 2015 Q2 | 236.59 Thousand CAD | 13.05% |
| 2014 FY | 2.88 Million CAD | 1493.6% |
| 2014 Q3 | 2.05 Million CAD | 3907.0% |
| 2014 Q4 | 706.11 Thousand CAD | -65.72% |
| 2014 Q2 | 51.4 Thousand CAD | -22.11% |
| 2014 Q1 | 65.99 Thousand CAD | 0.0% |
| 2013 FY | 180.99 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Izotropic Corporation | 1.56 Million CAD | 5.581% |
| Sona Nanotech Inc. | 2.43 Million CAD | 39.173% |